Quantcast
Last updated on April 17, 2014 at 14:51 EDT

Latest gentamicin Stories

2014-04-01 13:02:44

Antibiotics being explored for the treatment of cystic fibrosis and muscular dystrophy have the potential to trigger autoimmune disease The code for every gene includes a message at the end of it that signals the translation machinery to stop. Some diseases, such as cystic fibrosis and Duchenne muscular dystrophy, can result from mutations that insert this stop signal into the middle of an essential gene, causing the resulting protein to be truncated. Some antibiotics cause the cell's...

2013-12-31 23:02:31

American Hearing & Balance's Audiologists wish to inform the public about the fact that a large number of common drugs are harmful to hearing. Marina del Rey, CA (PRWEB) December 31, 2013 Both over-the-counter and doctor-prescribed drugs can be ototoxic. The American Speech-Language-Hearing Association states that there exist more than two hundred known ototoxic medications, of which many are used commonly. In order to make it easier for consumers to identify the ototoxic...

How To Create Antibiotics That Don't Hurt Hearing
2012-06-12 06:52:11

Apramycin, already used in animals, shows promise against drug-resistant TB and other 'superbugs,' without hearing loss The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria — but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells...

2012-06-11 10:24:04

Apramycin, already used in animals, shows promise against drug-resistant TB and other "superbugs", without hearing loss ANN ARBOR, Mich., June 11, 2012 /PRNewswire-USNewswire/ -- The world needs new antibiotics to overcome the ever-increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill...

2010-07-13 06:00:00

ASHBURN, Va., July 13 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia(TM): Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers. The protocol was developed following an End of Phase 2 meeting with FDA where the results of Innocoll's phase 2 clinical studies were...

2010-01-28 10:34:59

A type of antibiotic that can cause hearing loss in people has been found to paradoxically protect the ears when given in extended low doses in very young mice. The surprise finding came from researchers at Washington University School of Medicine in St. Louis who looked to see if loud noise and the antibiotic kanamycin together would produce a bigger hearing loss than either factor by itself. The results will appear in an upcoming issue of the Journal of the Association for Research in...

2009-06-18 06:00:00

ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers. Chronic ulcerations such as diabetic foot ulcers are often colonized or contaminated with bacterial pathogens that can prevent ulcers...

2009-03-19 06:00:00

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections. The trial is being conducted at approximately 45 hospital sites across the U.S. and has enrolled 600 patients undergoing...

2009-03-16 06:00:00

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections. The trial is being conducted at approximately 50 hospital sites across the U.S. and has enrolled 1,500 diabetic and/or...

2008-08-25 09:01:58

DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and...